Abstract 17331: Statins and Venous Thromboembolism: Systematic Review and Meta-analysis of Prospective Cohort and Randomized Intervention Studies
Introduction: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is associated with significant morbidity and mortality. Statins, which are well established for their lipid-lowering properties, have also been suggested to have a protective effect on VTE outcomes, but the evidence is still uncertain.
Hypothesis: Statins may be protective of VTE risk.
Methods: We conducted a systematic review and meta-analysis of observational cohort studies and randomized controlled trials (RCTs) reporting on the associations between statins and VTE outcomes.
Data sources included MEDLINE, EMBASE, Web of Science, Cochrane Library, and manual search of bibliographies to May 2016. Study specific relative risks (RRs) with 95% confidence intervals were aggregated using random effects models and were grouped by study level characteristics.
Results: There were 36 eligible studies (13 cohort studies comprising 3,148,259 participants and 23 RCTs of statins versus placebo or no treatment comprising 118,464 participants) included in the review. In observational studies, the pooled RR for VTE was 0.75 (0.65-0.87) when comparing statin use with no use. This association remained consistent when grouped by various study level characteristics. In RCTs, the RR for VTE was 0.85 (0.73-0.99) comparing statin therapy with placebo or no treatment. Subgroup analyses suggested significant differences in the effect of statins by type of statin, with rosuvastatin having the lowest risk on VTE compared to other statins 0.57 (0.42-0.75).
Conclusions: Available evidence from observational and intervention studies indicate a protective effect of statin use in the primary prevention of VTE. In intervention studies, therapy with rosuvastatin significantly reduced VTE compared to other statins.
Figure Effect of statin therapy on venous thromboembolism in randomized controlled trials CI, confidence interval (bars); RR, relative risk
Author Disclosures: S.K. Kunutsor: None. S. Seidu: None. K. Khunti: None.
- © 2016 by American Heart Association, Inc.